Intech Biopharm Ltd Market Cap ($95.93 Million)
Market Cap & Net Worth: Intech Biopharm Ltd (6461)
Intech Biopharm Ltd market cap. Intech Biopharm Ltd (TWO:6461) has a market capitalization of $95.93 Million (NT$3.04 Billion) as of November 5, 2026. Listed on the TWO stock exchange, this Taiwan-based company holds position #19182 globally and #1080 in its home market, demonstrating a 4.94% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Intech Biopharm Ltd's stock price NT$27.60 by its total outstanding shares 110324527 (110.32 Million). Also see how efficiently does Intech Biopharm Ltd generate cash for how efficiently the company converts equity into cash flow.
Intech Biopharm Ltd Market Cap History (2015–2026)
Intech Biopharm Ltd market cap history from 2015 to 2026. Data shows change from $168.06 Million to $95.93 Million (-3.05% CAGR). Check 6461 stock price for real-time trading data and today's change.
Intech Biopharm Ltd Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Intech Biopharm Ltd's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Explore 6461 net assets growth trend to track how rapidly the company is growing its equity base year over year.
Latest Price to Sales (P/S) Ratio
0.58x
Intech Biopharm Ltd's market cap is 0.58 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2017 | $144.53 Million | $16.61 Million | -$239.31 Million | 8.70x | N/A |
| 2018 | $65.24 Million | $17.23 Million | -$222.07 Million | 3.79x | N/A |
| 2019 | $63.96 Million | $16.68 Million | -$311.42 Million | 3.83x | N/A |
| 2020 | $71.95 Million | $21.11 Million | -$250.37 Million | 3.41x | N/A |
| 2021 | $69.52 Million | $38.90 Million | -$301.76 Million | 1.79x | N/A |
| 2022 | $115.57 Million | $23.65 Million | -$327.88 Million | 4.89x | N/A |
| 2023 | $103.93 Million | $25.85 Million | -$337.99 Million | 4.02x | N/A |
| 2024 | $91.76 Million | $39.78 Million | -$368.21 Million | 2.31x | N/A |
| 2025 | $61.87 Million | $107.53 Million | -$389.03 Million | 0.58x | N/A |
Competitor Companies of 6461 by Market Capitalization
Companies near Intech Biopharm Ltd in the global market cap rankings as of November 5, 2026. Also see Intech Biopharm Ltd total assets for a full breakdown of the balance sheet.
Key companies related to Intech Biopharm Ltd by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #181 globally with a market cap of $130.90 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #373 globally with a market cap of $76.14 Billion USD.
- CSL Ltd (AU:CSL): Ranked #415 globally with a market cap of $67.74 Billion USD ( AU$95.74 Billion AUD).
- Moderna Inc (NASDAQ:MRNA): Ranked #503 globally with a market cap of $54.14 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #181 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $130.90 Billion | $549.04 |
| #373 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $76.14 Billion | $930.67 |
| #415 | CSL Ltd | AU:CSL | $67.74 Billion | AU$197.34 |
| #503 | Moderna Inc | NASDAQ:MRNA | $54.14 Billion | $258.38 |
Market Capitalization of Intech Biopharm Ltd (2015–2026)
Market capitalization of Intech Biopharm Ltd from 2015 to today. Between 2015 and today, Intech Biopharm Ltd's market cap moved from $168.06 Million to $ 95.93 Million, with a yearly change of -3.05%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | NT$95.93 Million | +55.06% |
| 2025 | NT$61.87 Million | -32.58% |
| 2024 | NT$91.76 Million | -11.71% |
| 2023 | NT$103.93 Million | -10.08% |
| 2022 | NT$115.57 Million | +66.25% |
| 2021 | NT$69.52 Million | -3.38% |
| 2020 | NT$71.95 Million | +12.50% |
| 2019 | NT$63.96 Million | -1.98% |
| 2018 | NT$65.24 Million | -54.86% |
| 2017 | NT$144.53 Million | +20.67% |
| 2016 | NT$119.77 Million | -28.73% |
| 2015 | NT$168.06 Million | -- |
End of Day Market Cap According to Different Sources
On Nov 5th, 2026 the market cap of Intech Biopharm Ltd was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $95.93 Million USD |
| MoneyControl | $95.93 Million USD |
| MarketWatch | $95.93 Million USD |
| marketcap.company | $95.93 Million USD |
| Reuters | $95.93 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Intech Biopharm Ltd
Intech Biopharm Corporation engages in developing and manufacturing generic drugs to treat respiratory diseases in Taiwan and internationally. The company offers combinations, formulations, and generic drugs for the treatment of respiratory diseases using technology platforms, such as inhaled low ethanol formulation, a metered dose inhaler platform for treating asthma and COPD, as well as dry pow… Read more